Neurodevelopmental Intervention for Preterm Infants
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores ways to support brain development in preterm infants using a special combination of activities. The research examines the effects of skin-to-skin contact and calming sensory experiences, such as hearing a parent's voice and smelling breast milk, to determine if they aid in the babies' growth. Participants will be divided into two groups: one will receive only skin-to-skin care (SSC alone), while the other will receive additional sensory experiences as part of the NeuroN-QI (Nurturing and Quiet Intervention) program. This trial suits parents of preterm infants born between 24 and 33 weeks who are ready for skin-to-skin contact and can provide breast milk. As an unphased trial, this study offers a unique opportunity for parents to contribute to innovative research that could enhance care for preterm infants.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications. However, infants still receiving certain medications like analgesics (pain relievers), sedatives, or paralyzing agents are excluded from the trial.
What prior data suggests that this intervention is safe for preterm infants?
Research has shown that NeuroN-QI, which involves skin-to-skin contact and sound stimulation, is safe for premature babies. Earlier studies examined its practicality and acceptability, finding it well-received. Although detailed safety reports are not highlighted, the emphasis on acceptability suggests no major safety concerns.
For skin-to-skin contact (SSC) alone, studies have demonstrated its safety for premature babies. It does not cause issues like dislodging or breaking medical tubes, indicating it is well-tolerated. SSC is a common practice in newborn care, known to support growth and reduce mortality rates in low birth weight infants.
Both methods emphasize gentle care, which is generally safe and beneficial for babies' development.12345Why are researchers excited about this trial?
Researchers are excited about this trial because it explores innovative ways to support the development of preterm infants through sensory stimulation techniques. Unlike traditional care methods such as standard skin-to-skin contact (SSC), the NeuroN-QI treatment adds an extra layer of sensory engagement by incorporating auditory stimulation and controlled environments. This approach includes parents reading to their infants during SSC and using breast milk's scent to promote calm periods, which could enhance neurodevelopmental outcomes. By integrating these elements, the trial aims to discover if these added sensory experiences can provide more significant benefits than the current standard of care.
What evidence suggests that this trial's treatments could be effective for neurodevelopment in preterm infants?
Studies have shown that skin-to-skin contact (SSC), or kangaroo care, has lasting positive effects on preterm infants. It aids brain development and enhances thinking skills. In this trial, one group of participants will receive only SSC, which is crucial for both short- and long-term health outcomes. Another group will receive the NeuroN-QI intervention, which incorporates sounds and smells into SSC. Early findings suggest that these additional sensory experiences, combined with a calm environment, could further support brain development in preterm infants.12456
Are You a Good Fit for This Trial?
This trial is for preterm infants born between 24 and nearly 34 weeks of gestational age, who are stable enough for skin-to-skin contact (SSC). Parents must commit to at least one SSC session per week with auditory stimulation until the infant reaches 36 weeks of gestational age. Mothers should be expressing breast milk for their infants. In case of twins, fathers can also participate.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Intervention
Parents and preterm infants engage in skin-to-skin contact and auditory stimulation, followed by a calm period with olfactory stimulation, until the infants reach 36 weeks gestational age.
Follow-up
Participants are monitored for neurodevelopmental outcomes and parental stress and anxiety levels.
What Are the Treatments Tested in This Trial?
Interventions
- NeuroN-QI
- SSC alone
Find a Clinic Near You
Who Is Running the Clinical Trial?
St. Justine's Hospital
Lead Sponsor